3HAA for Health & Longevity - Quick Reference Sheet

3HAA for Health & Longevity

Created on 07/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

3HAA is a natural molecule made as the body breaks down a dietary amino acid. Animal studies link higher levels to longer, healthier lives, likely by strengthening cells' stress resistance and calming inflammation. No human trial has tested it, its chemistry can turn damaging at high levels, and regular endurance exercise is the one proven way to raise it. (Full Review)

Protocol

Lifestyle Elevation
Endurance exercise
Only route shown to raise 3HAA in humans
Dietary Supplementation
No human dose
Fed to aging mice; no established human regimen
HAAO Inhibition
Not clinically available
Slows 3HAA breakdown; largest animal lifespan effect
Time to effect
Healthspan / Lifespan
Weeks to lifelong
Animal effects developed over weeks; unknown in humans
3HAA Level Rise
~6 months
Endurance exercise raised serum 3HAA in humans

Benefits

Contraindications
  • Active cancer immunotherapy (immune-checkpoint inhibitors)
  • Pregnancy or breastfeeding
  • Iron- or copper-overload disorders (hemochromatosis with transferrin saturation >45%, Wilson's disease)
  • Post-menopausal or established low bone density (T-score < −1.0)
Key Interactions
  • Kynurenine-pathway drugs (IDO/TDO inhibitors: epacadostat, linrodostat)
  • Iron & copper supplements, high-dose vitamin C with iron
  • NAD⁺-boosting supplements (nicotinamide riboside, nicotinamide mononucleotide)
  • Tryptophan & 5-HTP supplements
  • Vitamin B6 (deficiency or mega-dosing)
  • Immunosuppressive agents (corticosteroids, methotrexate, cyclosporine, tacrolimus, high-dose curcumin, omega-3s)

Risk & Side Effects

  • Low: Pro-oxidant activity & oxidative cytotoxicity; impaired bone formation & reduced bone density
  • Speculative: DNA damage & cellular senescence at high levels; shunting toward neurotoxic quinolinic acid; unknown human safety & absence of dosing data

Monitoring

Marker Target Why
Serum 3-hydroxyanthranilic acid (3HAA) No established range (low nanomolar, assay-dependent) Direct level of the metabolite of interest
Kynurenine-to-tryptophan ratio ~20–40 µmol/mmol Reflects activity of the pathway that feeds 3HAA
Serum tryptophan 45–80 µmol/L Substrate availability for the whole pathway
Kynurenine 1.4–2.5 µmol/L Upstream precursor and marker of pathway flux
High-sensitivity C-reactive protein <1.0 mg/L Systemic inflammation that drives flux into this pathway
Ferritin 50–150 ng/mL Iron stores; excess iron amplifies 3HAA's pro-oxidant chemistry
Serum copper 70–110 µg/dL Copper can drive 3HAA-related free-radical damage
Vitamin B6 (plasma PLP) 30–110 nmol/L Cofactor for the enzyme making 3HAA's precursor
Bone mineral density (T-score) ≥ −1.0 Screens for the bone-loss risk suggested by animal data

Cadence: Every 6–12 months; focused recheck 8–12 weeks after a change; bone density every 1–2 years

Qualitative Assessment

  • Energy and vitality
  • Exercise recovery
  • Cognitive clarity
  • Inflammatory symptoms
  • Sleep quality